Evaxion reports 69% overall response rate in Phase 2 study of lead cancer vaccine candidate EVX-01 Page 1

• Topline data from a one-year interim analysis of the ongoing Phase 2 study show that 11 of 16 patients had objective clinical responses, representing an overall response rate of 69%
• In 15 of 16 patients, the tumors (target lesions) shrank
• The complete one-year dataset will be presented at the ESMO Congress this week and discussed in a webinar with key opinion leaders. Professor Georgina V. Long on September 18, 2024

COPENHAGEN, Denmark, Sept. 9, 2024 (GLOBE NEWSWIRE) — Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company focused on developing AI immunology-driven vaccines, announces new exciting Phase 2 clinical data for its lead compound EVX-01. The data show that 11 of 16 patients experienced objective clinical responses, representing an overall response rate (ORR) of 69%. Fifteen of the 16 patients experienced shrinkage of their tumors (target lesions).

These topline data are part of a one-year interim analysis of the ongoing Phase 2 study evaluating EVX-01 in combination with MSD's (Merck & Co., Inc., Rahway, NJ, USA) anti-PD-1 therapy KEYTRUDA (pembrolizumab) in patients with advanced melanoma (skin cancer). The full one-year clinical data will be presented at a poster session at the 2024 European Society for Medical Oncology (ESMO) Congress, to be held September 13-17, 2024 in Barcelona, ​​Spain.